Agile Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Agile Therapeutics generated cash of -$9,577,000, which is more than the previous year. Cash used in financing activities reached the amount of $6,888,000 last year. Net change in cash is therefore -$2,689,000.
Cash Flow
| 2014 | -14.50M | -95.73K | 52.66M |
|---|---|---|---|
| 2015 | -25.47M | -290K | 19.98M |
| 2016 | -23.30M | -31K | 37.68M |
| 2017 | -24.56M | -1.31M | 13.07M |
| 2018 | -16.89M | -318K | -10.88M |
| 2019 | -15.68M | -98K | 42.41M |
| 2020 | -47.31M | -40.69M | 67.98M |
| 2021 | -65.20M | 39.46M | 30.42M |
| 2022 | -35.94M | -133K | 22.18M |
| 2023 | -9.57M | 0 | 6.88M |
AGRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 5.24M | 19.14M | 14.46M | 34.47M | 7.85M | 35.95M | 48.75M | 34.39M | 40.18M | 2.11M |
Operating activities | ||||||||||
Net income | -14.46M | -25.41M | -74.89M | -51.85M | -18.60M | -19.77M | -28.30M | -28.74M | -30.33M | -16.07M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 386K | 1.53M | 2.22M | 276K | 163K | 23K | 23K | 19K | 18K | 12.55K |
Stock-based compensation expense | 1.98M | 2.49M | 3.33M | 2.81M | 1.76M | 0 | 3.65M | 3.42M | 2.96M | 1.38M |
| Deferred income tax benefit | 1.98M | 2.49M | 3.33M | 2.81M | 1.76M | 0 | 3.65M | 3.42M | 2.96M | 1.38M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -15K | -1.84M | -668K | -865K | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -2.20M | -366K | -6.28M | -3.64M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | -628K | 5.20M | 3.64M | 1.37M | -1.17M | -2.46M | 362K | 1.34M | 2.59B |
Cash generated by operating activities | -9.57M | -35.94M | -65.20M | -47.31M | -15.68M | -16.89M | -24.56M | -23.30M | -25.47M | -14.50M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -54.83M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -133K | -269K | -353K | -98K | -318K | -1.31M | -31K | -290K | -95.73K |
Acquisitions Net | 0 | 0 | 0 | 353K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | -133K | 39.46M | -40.69M | -98K | -318K | -1.31M | -31K | -290K | -95.73K |
Financing activities | ||||||||||
Common Stock Issued | 8.23M | 35.43M | 30.34M | 49.04M | 42.25M | 0 | 18.53M | 37.52M | 19.33M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -1.34M | -17.37M | -131K | -18.94M | 0 | -10.88M | -5.61M | -985K | 481K | 0 |
Cash used in financing activities | 6.88M | 22.18M | 30.42M | 67.98M | 42.41M | -10.88M | 13.07M | 37.68M | 19.98M | 52.66M |
Net Change In Cash | -2.68M | -13.89M | 4.68M | -20.01M | 26.62M | -28.10M | -12.79M | 14.35M | -5.78M | 38.06M |
Cash at end of period | 2.55M | 5.24M | 19.14M | 14.46M | 34.47M | 7.85M | 35.95M | 48.75M | 34.39M | 40.18M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |